Alivira, Boehringer Ingelheim India Partner
Analysis based on 6 articles · First reported Jan 22, 2026 · Last updated Jan 24, 2026
The partnership between Sequent Scientific — Alivira Animal Health Limited and Boehringer Ingelheim is expected to positively impact the animal health market in India by increasing access to innovative medicines and expanding sales capabilities. This collaboration could lead to increased revenue and market share for both companies, particularly for Viyash Scientific Limited, the parent company of Sequent Scientific — Alivira Animal Health Limited.
Sequent Scientific — Alivira Animal Health Limited, a subsidiary of Viyash Scientific Limited, has formed a strategic partnership with Boehringer Ingelheim for the distribution and promotion of companion animal products across India. This collaboration aims to capitalize on the burgeoning pet healthcare market in India, driven by increased pet ownership and awareness of animal well-being. The agreement will leverage Sequent Scientific — Alivira Animal Health Limited's extensive geographical reach and on-ground capabilities with Boehringer Ingelheim's differentiated product portfolio to better serve veterinarians and pet parents. This move aligns with the long-term growth strategies of both companies, enhancing market access and execution excellence in the companion animal business. The event also highlights the recent renaming of Sequent Scientific Limited to Viyash Scientific Limited, following its merger with Viyash Life Sciences Private Limited, effective January 8, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard